Fig. 1.
Haloperidol treatment in vivo elevates NIL α1D mRNA but not α1C or α1A mRNAs. A, Representative autoradiographs of RNase protection assays designed to measure α1D and α1C (top) or α1A (bottom) mRNAs, along with β-actin or cyclophilin mRNA for normalization. Gel lanes contain the following:Y, yeast RNA (50 μg); B,C, and H, total NIL RNA from bromocriptine, vehicle, and haloperidol treatment groups, respectively.B, Effect of 6 hr in vivo dopaminergic drug treatment on α1D (top;n = 6), α1C (middle;n = 3), and α1A(bottom; n = 4) mRNA levels. Quantitation was performed by phosphorimager analysis using short (1–3 hr) gel exposures. Note that only the effect of haloperidol on α1D mRNA was statistically significant.